Subscribe
agreement-istock-480052842_mediaphotos
mediaphotos / iStockphoto.com
7 April 2017Americas

Hikma enters settlement agreement with Jazz to sell Xyrem generic

Hikma Pharmaceuticals has entered into a settlement agreement with Jazz Pharmaceuticals, following a patent infringement dispute related to Jazz’s drug Xyrem (sodium oxybate).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
US court rejects Jazz attempt to revive Xyrem patents
17 July 2018   The US Court of Appeals for the Federal Circuit has rejected Jazz Pharmaceuticals’ attempt to revive patents covering its narcolepsy drug Xyrem.
Generics
Hikma ‘skinny’ label does not infringe Amarin patents
6 January 2022   Hikma Pharmaceuticals has secured a win in its “skinny label” patent suit with Amarin Pharmaceuticals, following a ruling handed down by a federal court in the state of Delaware.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
US court rejects Jazz attempt to revive Xyrem patents
17 July 2018   The US Court of Appeals for the Federal Circuit has rejected Jazz Pharmaceuticals’ attempt to revive patents covering its narcolepsy drug Xyrem.
Generics
Hikma ‘skinny’ label does not infringe Amarin patents
6 January 2022   Hikma Pharmaceuticals has secured a win in its “skinny label” patent suit with Amarin Pharmaceuticals, following a ruling handed down by a federal court in the state of Delaware.

More on this story

Americas
US court rejects Jazz attempt to revive Xyrem patents
17 July 2018   The US Court of Appeals for the Federal Circuit has rejected Jazz Pharmaceuticals’ attempt to revive patents covering its narcolepsy drug Xyrem.
Generics
Hikma ‘skinny’ label does not infringe Amarin patents
6 January 2022   Hikma Pharmaceuticals has secured a win in its “skinny label” patent suit with Amarin Pharmaceuticals, following a ruling handed down by a federal court in the state of Delaware.

More features

Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?
Pfizer infringed haemophilia therapy patent, says court